



2019 AAD Annual Meeting

Washington, DC • March 1-5, 2019

WALTER E. WASHINGTON CONVENTION CENTER

If you choose to submit Clinical Pearls in lieu of your presentation as a handout, please use this template.

Share the key takeaways and clinical pearls from your presentation with attendees.
Session Number and Title: 11249-A comparison of the efficacy and safety of fractional CO ₂ laser and fractional Er:YAG laser for the treatment of xanthelasma palpebrarum : a multicenter randomized split-face controlled trial
Presenter Name: Hsiao Han Tuan, MD
Clinical Pearls: Xanthelasma palpebrarum (XP) is a form of cutaneous xanthoma found on or around the eyelids. Currently, various type of lasers are widely used to treat XP. This study found that both fractional CO ₂ laser and fractional Er:YAG laser are effective and safe in treating XP, but fractional CO ₂ laser therapy appears more superior since fewer treatments are required for patients to show significant clinical improvement. Clinical controlled studies with more samples and longer follow-up period (e.g. three to five years of follow-up observations) are still needed.
References: Austin H. Nguyen, Adam M. Vaudreuil, and Christopher J. Huerter. Systematic review of laser therapy in xanthelasma palpebrarum .International Journal of Dermatology 2017, 56, e47–e55. 16. Esmat SM, Elramly AZ, Abdel Halim DM, et al. Fractional CO ₂ laser is an effective therapeutic modality for xanthelasma palpebrarum. Dermatol Surg. 2014; 40: 1349–1355.
Presenter's Email Address (Optional): dxha00337@btch.edu.cn